BioLineRx (BLRX) Short-term Investments (2021 - 2025)

BioLineRx has reported Short-term Investments over the past 5 years, most recently at $17.6 million for Q4 2025.

  • Quarterly results put Short-term Investments at $17.6 million for Q4 2025, up 93.14% from a year ago — trailing twelve months through Dec 2025 was $17.6 million (up 93.14% YoY), and the annual figure for FY2025 was $17.6 million, up 93.14%.
  • Short-term Investments for Q4 2025 was $17.6 million at BioLineRx, up from $9.1 million in the prior quarter.
  • Over the last five years, Short-term Investments for BLRX hit a ceiling of $44.1 million in Q4 2021 and a floor of $9.1 million in Q4 2024.
  • Median Short-term Investments over the past 5 years was $38.7 million (2023), compared with a mean of $30.0 million.
  • Biggest five-year swings in Short-term Investments: tumbled 76.44% in 2024 and later skyrocketed 93.14% in 2025.
  • BioLineRx's Short-term Investments stood at $44.1 million in 2021, then decreased by 8.27% to $40.5 million in 2022, then decreased by 4.34% to $38.7 million in 2023, then tumbled by 76.44% to $9.1 million in 2024, then surged by 93.14% to $17.6 million in 2025.
  • The last three reported values for Short-term Investments were $17.6 million (Q4 2025), $9.1 million (Q4 2024), and $38.7 million (Q4 2023) per Business Quant data.